Ann Marie Rogers won a landmark victory to make the breast cancer drug Herceptin more widely available. Here, she explains what drove her. But others are asking if the treatment really lives up to ...

Too many copies of the HER2 gene or its overexpression appeared to cause an especially aggressive form of the disease. By the late ’90s, a drug called Herceptin that targeted the HER2 receptor, sped ...

The FDA has approved Amgen and Allergan’s biosimilar of Roche’s Herceptin, just in time for the breast cancer blockbuster’s patent expiry. Herceptin’s main US patent expires this month ...

HER2-positive breast cancers can be very aggressive. For several years, the drug Herceptin has been used to treat women with HER2-positive breast cancer that has metastasized or recurred.

The new Herceptin formulation is now in phase 3 clinical trials, and if the program were successful, it would offer patients a convenient dosing form of the drug, which is currently given via ...

Mundipharma has signed a deal with Celltrion to market a biosimilar of Roche’s Herceptin (trastuzumab) in seven European countries. Breast cancer blockbuster Herceptin earned $2.26 billion in ...